These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7360100)

  • 1. Bromo-DMA: new hallucinogenic drug.
    Delliou D
    Med J Aust; 1980 Jan; 1(2):83. PubMed ID: 7360100
    [No Abstract]   [Full Text] [Related]  

  • 2. Bromo-DMA: the Australasian hallucinogen?
    Buhrich N; Morris G; Cook G
    Aust N Z J Psychiatry; 1983 Sep; 17(3):275-9. PubMed ID: 6580896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and quantitation of 4-bromo-2,5-dimethoxyamphetamine in seized blotters.
    Burrai L; Nieddu M; Palomba M; Pirisi MA
    Leg Med (Tokyo); 2015 Jan; 17(1):56-9. PubMed ID: 25248801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behavioral effects of 2,5-dimethoxy-4-alkyl amphetamines.
    Morin RD; Benington F; Mitchell SR; Beaton JM; Bradley RJ; Smythies JR
    Experientia; 1975 Jan; 31(1):93-5. PubMed ID: 234850
    [No Abstract]   [Full Text] [Related]  

  • 5. 4-Bromo-2,5-dimethoxyphenethylamine: identification of a new street drug.
    Ragan FA; Hite SA; Samuels MS; Garey RE
    J Anal Toxicol; 1985; 9(2):91-3. PubMed ID: 3990254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A death due to 4-bromo-2,5-dimethoxyamphetamine.
    Winek CL; Collom WD; Bricker JD
    Clin Toxicol; 1981 Mar; 18(3):267-71. PubMed ID: 7237958
    [No Abstract]   [Full Text] [Related]  

  • 7. [Studies on the identification of psychotropic substances. VI. Preparation and various analytical data of reference standards of some hallucinogens, 2,5-dimethoxy-4-methylamphetamine (STP), 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-ethylamphetamine (DOET)].
    Shimamine M; Takahashi K; Nakahara Y
    Eisei Shikenjo Hokoku; 1989; (107):113-9. PubMed ID: 2636911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged Psychosis With Catatonia due to 2,5-Dimethoxy-4-Bromoamphetamine: Case Report and Literature Review.
    Scarella TM; Teslyar P
    Psychosomatics; 2019; 60(6):599-602. PubMed ID: 30583875
    [No Abstract]   [Full Text] [Related]  

  • 9. Electrochemical study of the hallucinogen (+-)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane.
    Richter P; Morales A; Gómez-Jeria JS; Morales-Lagos D
    Analyst; 1988 Jun; 113(6):859-63. PubMed ID: 3218759
    [No Abstract]   [Full Text] [Related]  

  • 10. A reevaluation of psychotomimetic amphetamine derivatives in humans.
    Cassels BK; Gómez-Jeria JS
    J Psychoactive Drugs; 1985; 17(2):129-30. PubMed ID: 4020537
    [No Abstract]   [Full Text] [Related]  

  • 11. Profiles of psychedelic drugs: 10. DOB.
    Shulgin A
    J Psychoactive Drugs; 1981; 13(1):99. PubMed ID: 7277091
    [No Abstract]   [Full Text] [Related]  

  • 12. LSD or DOB?
    Davis WM
    Am J Psychiatry; 1982 Dec; 139(12):1649. PubMed ID: 7149079
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion.
    Bowen JS; Davis GB; Kearney TE; Bardin J
    JAMA; 1983 Mar; 249(11):1477-9. PubMed ID: 6827726
    [No Abstract]   [Full Text] [Related]  

  • 14. Neurological aspects of hallucinogenic drugs.
    Logan WJ
    Adv Neurol; 1975; 13():47-78. PubMed ID: 814800
    [No Abstract]   [Full Text] [Related]  

  • 15. 4-bromo-2,5-dimethoxyamphetamine: psychoactivity, toxic effects and analytical methods.
    Delliou D
    Forensic Sci Int; 1983; 21(3):259-67. PubMed ID: 6873782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of behavioral properties of di- and tri-methoxyphenylisopropylamines.
    Glennon RA; Young R
    Pharmacol Biochem Behav; 1982 Oct; 17(4):603-7. PubMed ID: 6965276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.
    Nichols DE; Hoffman AJ; Oberlender RA; Riggs RM
    J Med Chem; 1986 Feb; 29(2):302-4. PubMed ID: 3950910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane.
    Oberlender RA; Kothari PJ; Nichols DE; Zabik JE
    J Med Chem; 1984 Jun; 27(6):788-92. PubMed ID: 6737421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.